Opportunistic and systemic fungi

Infectious Diseases: Third Edition

Volumn 2, Issue , 2010, Pages 1823-1852

  Mitchell, Thomas G ^a   Verweij, Paul ^b   Hoepelman, Andy I M ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866352907     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-04579-7.00178-7     Document Type: Chapter

References (124)

1. Langenbeck B. Auffingung von Pilzen aus der Schleimhaut der Speiserohre einer Typhus-Leiche. Neue Not Geb Natur Heilk (Froriep) 1839, 12:145-147.
2. Jarvis W.R. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995, 20:1526-1530.
3. Pfaller M.A., Diekema D.J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007, 20:133-163.
4. Pfaller M.A. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001, 39:3254-3259.
5. Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 2001, 33:1692-1696.
6. Safdar N., Maki D.G. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, Enterococcus, Gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 2002, 136:834-844.
7. Rocco T.R., Reinert S.E., Simms H. Effect of fluconazole administration in critically ill patients. Arch Surg 2000, 135:160-165.
8. Abi-Said D., Anaissie E., Uzun O., Raad I., Pinzcowski H., Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997, 24:1122-1128.
9. Marr K.A., Seidel K., Slavin M.A., et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogenic marrow transplant recipients: long-term follow-up of a randomized, placebo controlled trial. Blood 2000, 96:2055-2061.
10. Kanda Y., Yamamoto R., Chizuka A., et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. Cancer 2000, 89:1611-1625.
11. Neofytos D., Horn D., Anaissie E., et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009, 48:265-273.
12. Matthews R.C. Pathogenicity determinants of Candida albicans: potential targets for immunotherapy?. Microbiology 1994, 140:1505-1511.
13. Kirkpatrick C.H. Chronic mucocutaneous candidiasis. Candidiasis. Pathogenesis, diagnosis and treatment 1993, 167-184. Raven Press, New York. 2nd ed. G.P. Bodey (Ed.).
14. Ferwerda B., Ferwerda G., Plantinga T.S., et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med 2009, 361:1760-1767.
15. Glocker E.O., Hennigs A., Nabavi M. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med 2009, 361:1727-1735.
16. Netea M.G., Brown G.D., Kullberg B.J., Gow N.A. An integrated model of the recognition of Candida albicans by the innate immune system. Nat Rev Microbiol 2008, 6:67-78.
17. Meyer M.H., Letscher-Bru V., Jaulhac B., Waller J., Candolfi E. Comparison of Mycosis IC/F and Plus Aerobic/F media for diagnosis of fungemia by the Bactec 9240 system. J Clin Microbiol 2004, 42:773-777.
18. Shepard J.R., Addison R.M., Alexander B.D., et al. Multicenter evaluation of the Candida albicans/Candida glabrata peptide nucleic acid fluorescent in situ hybridization method for simultaneous dual-color identification of C. albicans and C. glabrata directly from blood culture bottles. J Clin Microbiol 2008, 46:50-55.
19. Morrell M., Fraser V.J., Kollef M.H. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005, 49:3640-3645.
20. Garey K.W., Rege M., Pai M.P., et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006, 43:25-31.
21. Sendid B., Poirot J.L., Tabouret M., et al. Combined detection of mannanaemia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species. J Med Microbiol 2002, 51:433-442.
22. Ostrosky-Zeichner L., Alexander B.D., Kett D.H., et al. Multicenter clinical evaluation of the (1®3) beta- d-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005, 41:654-659.
23. Digby J., Kalbfleisch J., Glenn A., Larsen A., Browder W., Williams D. Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. Clin Diagn Lab Immunol 2003, 10:882-885.
24. Mennink-Kersten M.A., Ruegebrink D., Verweij P.E. Pseudomonas aeruginosa as a cause of 1,3-beta- d-glucan assay reactivity. Clin Infect Dis 2008, 46:1930-1931.
25. Verduyn Lunel F.M., Donnelly J.P., van der Lee H.A., Blijlevens N.M., Verweij P.E. Circulating Candida-specific anti-mannan antibodies precede invasive candidiasis in patients undergoing myelo-ablative chemotherapy. Clin Microbiol Infect 2009, 15:380-386.
26. Lunel F.M., Mennink-Kersten M.A., Ruegebrink D., et al. Value of Candida serum markers in patients with invasive candidiasis after myeloablative chemotherapy. Diagn Microbiol Infect Dis 2009, 64(4):408-415.
27. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard 2008, Clinical and Laboratory Standards Institute, CLSI, Wayne, PA, (M27-A3). 3rd ed.
28. EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect 2008, 14:398-405. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST).
29. Rambali B., Fernandez J.A., Van Nuffel L., et al. Susceptibility testing of pathogenic fungi with itraconazole: a process analysis of test variables. J Antimicrob Chemother 2001, 48:163-177.
30. Rodríguez-Tudela J.L., Almirante B., Rodríguez-Pardo D., et al. Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob Agents Chemother 2007, 51:3599-3604.
31. Pai M.P., Turpin R.S., Garey K.W. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother 2007, 51:35-39.
32. Perlin D.S. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 2007, 10:121-130.
33. Lundstrom T., Sobel J. Nosocomial candiduria: a review. Clin Infect Dis 2001, 32:1602-1607.
34. Crook W.G. The yeast connection, a medical breakthrough 1984, Vintage Books, New York. 2nd ed.
35. Renfro L., Feder H.M., Lane T.J., Manu P., Matthews D.A. Yeast connection among 100 patients with chronic fatigue. Am J Med 1989, 86:165-168.
36. Dismukes W.E., Wade J.S., Lee J.Y., Dockery B.K., Hain J.D. A randomized, double blind trial of nystatin therapy for the candidiasis hypersensitivity syndrome. N Engl J Med 1990, 323:1717-1723.
37. Candidiasis hypersensitivity syndrome. J Allergy Clin Immunol 1986, 78:271-273. Executive Committee of American Academy of Allergy and Immunology.
38. Pappas P.G., Kauffman C.A., Andes D., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535.
39. Hamza O.J., Matee M.I., Brüggemann R.J., et al. Single-dose fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, double-blind, double-dummy trial. Clin Infect Dis 2008, 47:1270-1276.
40. Blot S.I., Vandewoude K.H., De Waele J.J. Candida peritonitis. Curr Opin Crit Care 2007, 13:195-199.
41. Ostrosky-Zeichner L. Prophylaxis and treatment of invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2004, 23:739-744.
42. Hong S.B., Shin H.D., Hong J., et al. New taxa of Neosartorya and Aspergillus in Aspergillus section Fumigati. Antonie Van Leeuwenhoek 2008, 93:87-98.
43. Denning D.W. Invasive aspergillosis. Clin Infect Dis 1998, 26:781-805.
44. Pagano L., Caira M., Candoni A., et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006, 91:1068-1075.
45. Nivoix Y., Velten M., Letscher-Bru V., et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008, 47:1176-1184.
46. Tillie-Leblond I., Tonnel A.B. Allergic bronchopulmonary aspergillosis. Allergy 2005, 60:1004-1013.
47. Warris A., Klaassen C.H., Meis J.F., et al. Molecular epidemiology of Aspergillus fumigatus isolates recovered from water, air, and patients shows two clusters of genetically distinct strains. J Clin Microbiol 2003, 41:4101-4106.
48. Denning D.W. Aspergillosis: diagnosis and treatment. Int J Antimicrob Agents 1996, 6:161-168.
49. Levitz S.M. Overview of host defenses in fungal infection. Clin Infect Dis 1992, 14(Suppl.14):S37-42.
50. Perfect J.R., Cox G.M., Lee J.Y., et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis 2001, 33:1824-1833.
51. Pfeiffer C.D., Fine J.P., Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006, 42:1417-1427.
52. Klont R.R., Mennink-Kersten M.A., Verweij P.E. Utility of Aspergillus antigen detection in specimens other than serum specimens. Clin Infect Dis 2004, 39:1467-1474.
53. Mennink-Kersten M.A., Donnelly J.P., Verweij P.E. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004, 4:349-357.
54. Mennink-Kersten M.A., Verweij P.E. Non-culture-based diagnostics for opportunistic fungi. Infect Dis Clin North Am 2006, 20:711-727. viii.
55. De Pauw B., Walsh T.J., Donnelly J.P., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821.
56. Denning D.W., Riniotis K., Dobrashian R., Sambatakou H. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 2003, 37(Suppl.3):S265-280.
57. Greene R.E., Schlamm H.T., Oestmann J.W., et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007, 44:373-379.
58. Maertens J., Theunissen K., Verhoef G., et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005, 41:1242-1250.
59. Meersseman W., Lagrou K., Maertens J., et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 2008, 177:27-34.
60. Lass-Flörl C., Resch G., Nachbaur D., et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis 2007, 45:e101-104.
61. Verweij P.E., Mellado E., Melchers W.J. Multiple-triazole-resistant aspergillosis. N Engl J Med 2007, 356:1481-1483.
62. DeShazo R.D., Chapin K., Swain R.E. Fungal sinusitis. N Engl J Med 1997, 337:254-259.
63. Walsh T.J., Anaissie E.J., Denning D.W., et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:327-360.
64. Stevens D.A., Schwartz H.J., Lee J.Y., et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 2000, 342:756-762.
65. Verweij P.E., Howard S., Melchers W.J.G., Denning D.W. Azole resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat 2009, (in press).
66. Walsh T.J., Pappas P., Winston D.J., et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002, 346:225-234.
67. Schwartz S., Ruhnke M., Ribaud P., et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005, 106:2641-2645.
68. Herbrecht R., Denning D.W., Patterson T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347:408-415.
69. Marr K.A., Boeckh M., Carter R.A., Kim H.W., Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004, 39:797-802.
70. Cornely O.A., Maertens J., Winston D.J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007, 356:348-359.
71. Ullmann A.J., Lipton J.H., Vesole D.H., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007, 356:335-347.
72. Bovers M., Hagen F., Boekhout T. Diversity of the Cryptococcus neoformans- Cryptococcus gattii species complex. Rev Iberoam Micol 2008, 25:S4-S12.
73. Goldman D.L., Khine H., Abadi J., et al. Serological evidence for Cryptococcus neoformans infection in early childhood. Pediatrics 2001, 107:e66.
74. Kidd S.E., Hagen F., Tscharke R.L., et al. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci USA 2004, 101:17258-17263.
75. Park B.J., Wannemuehler K.A., Marston B.J., Govender N., Pappas P.G., Chiller T.M. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009, 23:525-530.
76. Singh N., Dromer F., Perfect J.R., Lortholary O. Cryptococcosis in solid organ transplant recipients: current state of the science. Clin Infect Dis 2008, 47:1321-1327.
77. Coenjaerts F.E.J., Walenkamp A.M.E., Hoepelman A.I.M. Potent inhibition of neutrophil migration by cryptococcal mannoprotein-4-induced desensitization. J Immunol 2001, 167:3988-3995.
78. Kwon-Chung K.J., Bennet J.E. Cryptococcis. Medical mycology 1992, 397-446. Lea and Febiger, Philadelphia.
79. Lipovsky M.M., Gekker G., Hu S., Ehrlich L.C., Hoepelman A.I., Peterson P.K. Cryptococcal glucuronoxylomannan induces IL-8 production by human microglia but inhibits neutrophil migration towards IL-8. J Infect Dis 1998, 177:260-263.
80. Speed B.R., Dunt D. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis 1995, 21:28-34.
81. Singh N., Alexander B.D., Lortholary O., et al. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis 2007, 195:756-764.
82. Brouwer A.E., Rajanuwong A., Chierakul W., et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004, 363:1764-1767.
83. Saag M.S., Graybill R.J., Larsen R.A., et al. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000, 30:710-718.
84. van der Horst C.M., Saag M.S., Cloud G.A., et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 1997, 337:15-21.
85. Dromer F., Bernede-Bauduin C., Guillemot D., et al. Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS One 2008, 3:e2870.
86. Pappas P.G., Chetchotisakd P., Larsen R.A., et al. A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis 2009, 48(12):1775-1783.
87. Emilie D., Burgard M., Lascoux-Combe C., et al. Cessation of secondary prophylaxis in patients with cryptococcosis. AIDS 2001, 15:1437-1438.
88. Shelburne S.A., Darcourt J., White C., et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis 2005, 40:1045-1052.
89. Lortholary O., Fontanet A., Memain N., Martin A., Sitbon K., Dromer F. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 2005, 19:1043-1049.
90. Hoffmann K., Discher S., Voigt K. Revision of the genus Absidia (Mucorales, Zygomycetes) based on physiological, phylogenetic, and morphological characters; thermotolerant Absidia spp. form a coherent group, Mycocladiaceae fam. nov. Mycol Res 2007, 111:1169-1183.
91. Marty F.M., Cosimi L.A., Baden L.R. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004, 350:950-952.
92. Roden M.M., Zaoutis T.E., Buchanan W.L., et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005, 41:634-653.
93. Sugar A.M. Mucormycosis. Clin Infect Dis 1992, 14(Suppl.1):126-129.
94. Yohai R.A., Bullock J.D., Aziz A.A., Markert R.J. Survival factors in rhino-orbital-cerebral mucormycosis. Surv Ophthalmol 1994, 39:3-22.
95. Spellberg B., Edwards J., Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005, 18:556-569.
96. Ibrahim A.S., Gebermariam T., Fu Y., et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007, 117:2649-2657.
97. Chamilos G., Marom E.M., Lewis R.E., Lionakis M.S., Kontoyiannis D.P. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 2005, 41:60-66.
98. Reed C., Bryant R., Ibrahim A.S., Edwards J., Filler S.G., Goldberg R., Spellberg B. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008, 47:364-371.
99. Chariyalertsak S., Sirisanthana T., Supparatpinyo K., Praparattanapan J., Nelson K.E. Case-control study of risk factors for Penicillium marneffei infection in human immunodeficiency virus-infected patients in northern Thailand. Clin Infect Dis 1997, 24:1080-1086.
100. Vanittanakom N., Cooper C.R., Fisher M.C., Sirisanthana T. Penicillium marneffei infection and recent advances in the epidemiology and molecular biology aspects. Clin Microbiol Rev 2006, 19:95-110.
101. Duong T.A. Infection due to Penicillium marneffei, an emerging pathogen: review of 155 reported cases. Clin Infect Dis 1996, 23:125-130.
102. Heath T.C.B., Patel A., Fisher D., Bowden F.J., Currie B. Disseminated Penicillium marneffei: presenting illness of advanced HIV infection; a clinicopathological review, illustrated by a case report. Pathology 1995, 27:101-105.
103. Nucci M., Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007, 20:695-704.
104. Anaissie E.J., Kuchar R.T., Rex J.H., et al. Fusariosis associated with pathogenic Fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis 2001, 33:1871-1878.
105. Larone D.H., Mitchell T.G., Walsh T.J. Histoplasma, Blastomyces, Coccidioides and other dimorphic fungi causing systemic mycoses. Manual of clinical microbiology 1999, 1259-1274. American Society for Microbiology, Washington DC. P.R. Murray, E.J. Baron, M.A. Pfaller, F.C. Tenover, Yolken (Eds.).
106. Nemecek J.C., Wuthrich M., Klein B.S. Global control of dimorphism and virulence in fungi. Science 2006, 312:583-588.
107. Mitchell T.G. Systemic mycoses. Zinsser microbiology 1992, 1091-1112. Appleton and Lange, Norwalk. 20th ed. W.K. Joklik, H.P. Willett, D.B. Amos, C.M. Wilfert (Eds.).
108. Kaufman L. Immunodiagnosis of blastomycosis. Blastomycosis 1992, 123-132. Plenum, New York. Y. Al-Doory, A.F. DiSalvo (Eds.).
109. Kaufman L., Reiss E. Serodiagnosis of fungal diseases. Manual of clinical laboratory immunology 1992, 506-528. American Society for Microbiology, Washington DC. N.R. Rose, E. Conway de Macario, J.L. Fahey, H. Friedman, G.M. Penn (Eds.).
110. Mitchell T.G. Serodiagnosis of mycotic infections. Diagnostic procedures for mycotic and parasitic infections 1988, 303-323. American Society for Microbiology, Washington DC. B.B. Wentworth (Ed.).
111. Hogan L.H., Klein B.S., Levitz S.M. Virulence factors of medically important fungi. Clin Microbiol Rev 1996, 9:469-488.
112. Huffnagle G.B., Deepe G.S. Innate and adaptive determinants of host susceptibility to medically important fungi. Curr Opin Microbiol 2003, 6:344-350.
113. Klein B.S., Chang W.-L. Pathogenic properties of Blastomyces dermatitidis. Fungal pathogenesis: principles and clinical applications 2002, 183-204. Marcel Dekker, New York. R.A. Calderone, R.L. Cihlar (Eds.).
114. Cutler J.E., Deepe G.S., Klein B.S. Advances in combating fungal diseases: vaccines on the threshold. Nat Rev Microbiol 2007, 5:13-28.
115. Walsh T.J., Larone D.H., Schell W.A., Mitchell T.G. Histoplasma, Blastomyces, Coccidioides, and other dimorphic fungi causing systemic mycoses. Manual of clinical microbiology 2003, 1781-1797. ASM Press, Washington DC. 8th ed. P.R. Murray, E.J. Baron, J.H. Jorgensen, M.A. Pfaller, R.H. Yolken (Eds.).
116. Chapman S.W., Dismukes W.E., Proia L.A., et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:1801-1812.
117. Freifeld A.G., Proia L.A., Andes D.R., et al. Voriconazole use for endemic fungal infections. Antimicrob Agents Chemother 2009, 53:1648-1651.
118. Fisher M.C., Koenig G.L., White T.J., Taylor J.W. Molecular and phenotypic description of Coccidioides posadasii sp. nov., previously recognized as the non-California population of Coccidioides immitis. Mycologia 2002, 94:73-84.
119. Kirkland T.N., Cole G.T. Coccidioidomycosis: pathogenesis, immune response, and vaccine development. Fungal pathogenesis: principles and clinical applications 2002, 365-399. Marcel Dekker, New York. R.A. Calderon, R.L. Cihlar (Eds.).
120. Woods J.P. Histoplasma capsulatum molecular genetics, pathogenesis, and responsiveness to its environment. Fungal Genet Biol 2002, 35:81-97.
121. Sebghati T.S., Engle J.T., Goldman W.E. Intracellular parasitism by Histoplasma capsulatum: fungal virulence and calcium dependence. Science 2000, 290:1368-1372.
122. Wheat L.J., Freifeld A., Kleiman M.B., et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007, 45:807-825.
123. Hajjeh R.A., Pappas P.G., Henderson H., et al. Multicenter case-control study of risk factors for histoplasmosis in human immunodeficiency virus-infected persons. Clin Infect Dis 2001, 32:1215-1220.
124. Salazar M.E., Restrepo A., Stevens D.A. Inhibition by estrogens of conidium-to-yeast conversion in the fungus Paracoccidioides brasiliensis. Infect Immun 1988, 56:711-713.